Cargando…

P1327: RUXOLITINIB COMBINED WITH GLUCOCORTICOID IN THE FIRST-LINE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN CHILDREN: A SINGLE CENTER RETROSPECTIVE STUDY

Detalles Bibliográficos
Autores principales:	Chen, K., Zou, B., Shao, J.-B., Liu, Q., Zhang, N., Fu, P., Sun, X.-H., Jiang, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430943/ http://dx.doi.org/10.1097/01.HS9.0000848172.50070.7a

Ejemplares similares

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

P1382: RUXOLITINIB USE IN A REAL WORLD ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE COHORT IN THE NETHERLANDS: A RETROSPECTIVE STUDY
por: Van Der Wagen, L., et al.
Publicado: (2022)

1327. Human Rhinovirus Infection in Multiple Myeloma Patients: Effect on Morbidity and Mortality
por: Hasan, Lana, et al.
Publicado: (2021)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
por: Abraham, P., et al.
Publicado: (2022)

Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients
por: Gagliardi, Thomas A, et al.
Publicado: (2022)

P1327: INHIBITING TELOMERIC DNA DAMAGE RESPONSE AS A NEW THERAPEUTIC STRATEGY TO REJUVENATE THE AGEING HEMATOPOIETIC SYSTEM
por: Oppezzo, Alessia, et al.
Publicado: (2023)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
por: Rodríguez-Gil, Alfonso, et al.
Publicado: (2022)

PO-1327 Prostate cancer radiotherapy in a COVID-19 pandemic year: experience of a chilean public hospital
por: Letelier, H., et al.
Publicado: (2021)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
por: Watson, Allison P., et al.
Publicado: (2018)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
por: Yang, Wenli, et al.
Publicado: (2021)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial
por: Isberner, Nora, et al.
Publicado: (2021)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

P1243: RUXOLITINIB COMBINED WITH DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INTERIM ANALYSIS OF A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE 2 CLINICAL TRIAL
por: Zhou, D., et al.
Publicado: (2022)

P1389: RUXOLITINIB DEMONSTRATES A GREATER CORTICOSTEROID-SPARING EFFECT THAN BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE
por: Zeiser, R., et al.
Publicado: (2022)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
por: Dou, Liping, et al.
Publicado: (2022)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease
por: Lin, Yan, et al.
Publicado: (2023)

A search for the radiative decay $Y^{*}_{0}(1327) \rightarrow \Lambda \gamma$
por: Mayeur, C, et al.
Publicado: (1970)

1327 Factors associated with optimizing empiric antibiotic therapy in six hospitals
por: Morgan, Daniel, et al.
Publicado: (2014)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

P1311: GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION FACILITATES ANTI-GRAFT-VERSUS-HOST DISEASE AND GRAFT-VERSUS-LEUKEMIA EFFECTS OF MUCOSA-ASSOCIATED INVARIANT T CELLS THROUGH DISTINCT FUNCTIONAL SUBSE
por: Gao, M., et al.
Publicado: (2022)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

PReS-FINAL-2127: Sclerodermatous graft versus host disease
por: Stevenson, JR, et al.
Publicado: (2013)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
por: Hinterlang, Mélanie, et al.
Publicado: (2022)

P1341: HAPLO-CORD VS HAPLOIDENTICAL TRANSPLANT IN 49 CHILDREN – A RETROSPECTIVE SINGLE CENTER ANALYSIS
por: Fu, P., et al.
Publicado: (2022)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

hTERT promoter polymorphism, -1327C>T, is associated with the risk of epithelial cancer
por: Iizuka, Toshihiko, et al.
Publicado: (2013)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5gps0e09gp8gbu7nmmfmgbrb2e